Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 15/20 | 0.45 |
| ▸ | MEN1 | O00255 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | GALK1 | P51570 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285900 | 1.00 | KMT2A (0.45) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL1286196 | 0.77 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1286195 | 0.77 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1286097 | 0.73 | PTGS2 (0.41) | LMNAHPGD | |
| SCHEMBL1286098 | 0.73 | PTGS2 (0.41) | LMNAHPGD | |
| SCHEMBL1285479 | 0.72 | TOP1 (0.47) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL1285477 | 0.72 | TOP1 (0.47) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL1286363 | 0.72 | PTGS1 (0.45) | KMT2AMEN1MAPTLMNAHPGD | |
| SCHEMBL633489 | 0.71 | PTGS1 (0.48) | KMT2AMEN1MAPTLMNA | |
| SCHEMBL6245187 | 0.71 | PTGS1 (0.34) | LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | RETROTOPE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148929-A2 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148930-A2 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2005033092-A1 | CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | KMT2A 4294/4885MEN1 4058/4885ALDH1A1 986/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | KMT2A 4294/4885MEN1 4058/4885ALDH1A1 986/4885 |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | KMT2A 3615/4885MEN1 4835/4885ALDH1A1 2738/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | KMT2A 3615/4885MEN1 4835/4885ALDH1A1 2738/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | KMT2A 3982/4885MEN1 4862/4885ALDH1A1 298/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | KMT2A 3939/4885MEN1 4885/4885ALDH1A1 437/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | KMT2A 3982/4885MEN1 4862/4885ALDH1A1 298/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | KMT2A 3939/4885MEN1 4885/4885ALDH1A1 437/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | KMT2A 3615/4885MEN1 4835/4885ALDH1A1 2738/4885 |
| US-20050065150-A1 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | ALOX12, ALOX15, ALOX15B | KMT2A 4416/4885MEN1 3367/4885ALDH1A1 1926/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | KMT2A 3041/4885MEN1 4192/4885ALDH1A1 54/4885 |
| US-11166930-B2 | Isotopically modified components and therapeutic uses thereof | ACADM, ALDH2, CPT1A | KMT2A 3249/4885MEN1 4140/4885ALDH1A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.